## KVUE: Kenvue Inc. - XLP: Consumer Defensive

### Executive Summary

VALUE thesis: PEG 0.88 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (51% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($16.74)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Norris Perne & French LLP MI Reduces Stock Holdings in Kenvue Inc. $KVUE**
- Source: MarketBeat | 20251229T123018 | Neutral | Relevance: 100%
- Norris Perne & French LLP MI decreased its stake in Kenvue Inc. by 25.1% in Q3, selling 178,615 shares and retaining 531,799 shares valued at approximately $8.63 million. This reduction comes amid varied institutional investor activity and a mixed Wall Street sentiment, with several analysts setting a "Hold" rating and an average price target of $20.23 for KVUE. Despite the reduction by Norris Perne & French, a director, Jeffrey C. Smith, significantly increased his holdings by purchasing 3.2 million shares for over $55 million.

**2. Mixed options sentiment in Kenvue Inc with shares up 0.38%**
- Source: MSN | 20251230T020759 | Somewhat-Bullish | Relevance: 100%
- This article, though having an incomplete content, indicates that Kenvue Inc (KVUE) has experienced a slight increase of 0.38% in its shares. The headline also suggests a mixed sentiment among options traders for the company.

**3. Johnson & Johnson ordered to pay $1.5B in baby powder case**
- Source: NJBIZ | 20251229T170801 | Somewhat-Bearish | Relevance: 88%
- A Baltimore jury has ordered Johnson & Johnson to pay over $1.5 billion to a Maryland woman who developed mesothelioma, an incurable cancer, after decades of using the company's talc-based baby powder. The verdict includes $59.84 million in compensatory damages and $1.5 billion in punitive damages, making it one of the largest verdicts against J&J for a single plaintiff. J&J plans to appeal, maintaining its talc products are safe and do not cause cancer, while also facing tens of thousands of other lawsuits regarding its talc products.

**4. Kimberly-Clark (KMB) Target Lowered as Citi Rebalances Household Care View**
- Source: Finviz | 20251230T152700 | Somewhat-Bullish | Relevance: 62%
- Citi lowered its price target on Kimberly-Clark Corporation (KMB) to $95 from $100 while maintaining a Sell rating, shifting its focus towards household and personal care companies for 2026. This rebalance comes as inventory destocking concludes, and consumption comparisons ease. Kimberly-Clark is also expanding its manufacturing in Vietnam and acquiring Kenvue, expecting significant cost synergies and growth in digital engagement.

**5. Activist Investor Toms Capital Is Buying Up Target Stock. Should You?**
- Source: Barchart.com | 20251229T210814 | Somewhat-Bullish | Relevance: 61%
- Activist hedge fund Toms Capital Investment Management (TCIM) has acquired a significant stake in Target Corporation (TGT), signaling potential pressure for strategic changes following Target's prolonged underperformance and sales slowdown. Despite a recent stock boost from the news, Target's shares are down over 27% year-to-date, reflecting continued challenges like cautious consumer spending and weak discretionary demand. Analysts maintain a cautious "Hold" rating on TGT stock, awaiting evidence of sustained growth before a re-rating.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (+0.0%)
- Blackrock Inc.: 7.6% (-1.9%)
- Price (T.Rowe) Assoc: 6.0% (-31.5%)
- State Street Corpora: 6.0% (-0.2%)
- FMR, LLC: 4.7% (-9.3%)

### Key Risks

1. Volume divergence: price rising (+2.7% MRS) on declining volume (51% of avg) suggests distribution.
2. Long-term trend broken: trading 13.4% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +2.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Forward P/E 15.7x stretched relative to 7% growth. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $33.2B |
| Beta | 0.56 |
| 52W Range | $14.02 - $25.17 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 15.7 |
| Current P/E | 16.8 |
| YoY Growth | 7.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.5% to 1.1% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >4.0% for momentum thesis). MRS_5 at 1.3% confirms short-term momentum alignment. Below SMA200 (0.87x), long-term trend not supportive. Volume at 51% of 20MA suggests lack of conviction. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.14% (CS: 68) | Neutral |
| RSI_14 | 60.3 | Neutral |
| MACD Histogram | -0.02 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.054x | Above |
| vs SMA200 | 0.866x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $17.34
- **Stop Loss:** $16.74 (3.5% risk)
- **Target:** $18.54 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1833
- **Position Value:** $31,784.22
- **Portfolio %:** 31.78%
- **Risk Dollars:** $1,100.00
- **Risk Per Trade:** 1.10%
- **Modifiers:** L1 110% | L2 100% | Combined 1.10x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-05 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.26 | $0.28 | +5.7% |
| 2025Q2 | $0.28 | $0.29 | +2.2% |
| 2025Q1 | $0.23 | $0.24 | +5.4% |
| 2024Q4 | $0.26 | $0.26 | +1.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*